652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)

Abstract

The VANCE trial (NCT 20578641) is the largest clinical trial of adoptive T cell therapy in solid tumors. This phase III, multicenter, randomized, open-label study evaluates the efficacy of GC followed by EBV-CTL versus GC alone as first-line treatment for locally recurrent but incurable and metastatic NPC (R/M). EBV-CTL is an autologous T-cell immunotherapy generated from blood of the patient and manufactured without genetic modification. Thirty clinical trial sites involved were from USA, Singapore, Malaysia, Taiwan and Thailand.